{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-23-000887","form_type":"8-K","ticker":"IGC","cik":"0001326205","company_name":"IGC Pharma, Inc.","filed_at":"2023-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.583409+00:00","generated_at":"2026-06-11T06:00:47.041102+00:00","sec_items":["5.07","8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"IGC Pharma shareholders pass all five proposals at 2023 annual meeting","bullets":["Claudia Grimaldi elected Class A director with 14.7M for, 1.4M withheld, 11M broker non-votes.","Ratified Manohar Chowdhry & Associates as auditor for FY2024: 26.9M for, 163K against.","Approved grant of 3M common shares to employees, advisors, directors; 14.3M for.","Say-on-pay approved (15.3M for); frequency set at every three years (13.1M for 3 yrs).","Board adopts triennial advisory vote on executive compensation going forward."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-23-000887","json":"https://secwatch.observer/filing/0001185185-23-000887.json","markdown":"https://secwatch.observer/filing/0001185185-23-000887.md","text":"https://secwatch.observer/filing/0001185185-23-000887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326205/000118518523000887/0001185185-23-000887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326205/000118518523000887/igcpharma20230821_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T06:00:47.041102+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12ff9898b0d7dad8c462e95ff8fb0a15c0dfd3b9","claim":"IGC Pharma, Inc. shareholders approved Approve grant of 3,000,000 shares of common stock to employees, advisors, directors, and consultants at the 2023-08-18 meeting.","evidence_excerpt":"For Against Abstain Broker Non-votes 14,268,013 1,861,386 39,115 11,035,662","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518523000887/0001185185-23-000887-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-18"}],"fact_type":"shareholder_vote"},{"claim_id":"2548932fe36fa4436cc5455279908d4e021b2a0b","claim":"IGC Pharma, Inc. shareholders approved Advisory vote on frequency of say-on-pay votes (every three years) at the 2023-08-18 meeting.","evidence_excerpt":"5. Approval to, by a non-binding advisory vote, setting the frequency of say-on-pay votes at future annual meetings of stockholders to every three years; 1 YEAR 2 YEARS 3 YEARS Abstain Broker Non-votes 2,429,382 181,013 13,078,308 479,811 11,035,662","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518523000887/0001185185-23-000887-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-18"}],"fact_type":"shareholder_vote"},{"claim_id":"7018af42aca7aee5c94822f4aa84495486f154c1","claim":"IGC Pharma, Inc. shareholders approved Election of Director Claudia Grimaldi at the 2023-08-18 meeting.","evidence_excerpt":"1. Election of Directors. Nominee For Withhold Broker Non-votes Claudia Grimaldi 14,740,248 1,428,266 11,035,662","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518523000887/0001185185-23-000887-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-18"}],"fact_type":"shareholder_vote"},{"claim_id":"8b5ac28876644b00284161598ed0210a2230399d","claim":"IGC Pharma, Inc. shareholders approved Advisory approval of compensation of named executive officers at the 2023-08-18 meeting.","evidence_excerpt":"4. Approval of a non-binding advisory resolution to approve the compensation of the Company’s named executive officers. For Against Abstain Broker Non-votes 15,339,051 769,054 60,409 11,035,662","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518523000887/0001185185-23-000887-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-18"}],"fact_type":"shareholder_vote"},{"claim_id":"dc8f7371a25e61c6d601f5ca7728bc792f2d8754","claim":"IGC Pharma, Inc. shareholders approved Ratify appointment of Manohar Chowdhry & Associates as independent registered public accounting firm for 2024 at the 2023-08-18 meeting.","evidence_excerpt":"2. Proposal to ratify the appointment of Manohar Chowdhry & Associates as the Company’s independent registered public accounting firm for the 2024 fiscal year. For Against Abstain 26,949,467 163,043 91,666","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518523000887/0001185185-23-000887-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-08-18"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}